Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.
DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.
Despite extensive clinical research, no disease-modifying treatment has been proven to alter the progression of Parkinson’s disease (PD). However, recent decades have seen significant advances in understanding its underlying neurodegenerative mechanisms, revealing new therapeutic targets. Immunotherapy, antisense oligonucleotides, and siRNA aim to prevent or reduce pathological protein aggregation and its spread throughout the brain, while cell therapy seeks to restore lost dopaminergic neurons. GLP-1 analogues hold promise for neuro-protection, and growing attention is being given to gut microbiota modulation. While challenges remain, these advances are driving renewed hope for a breakthrough in PD treatment. This article reviews the key strategies currently under investigation.